サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1360340

同種幹細胞市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年

Allogeneic Stem Cell Market (Type: Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant, and Donor Lymphocyte Infusion [DLI]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 204 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
同種幹細胞市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年
出版日: 2023年08月11日
発行: Transparency Market Research
ページ情報: 英文 204 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

同種幹細胞市場- レポートの範囲

世界の同種幹細胞市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界の同種幹細胞の収益を提供します。 2023年を基準年、2031年を予測年とみなして、2017年から2031年の期間の市場を分析します。レポートは、2023年から2031年までの世界の同種幹細胞市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、同種幹細胞市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書を参照することが含まれていました。

市場スナップショット
2023年の市場価値 9億4,180万米ドル
2031年の市場価値 16億米ドル
CAGR 6.3%

このレポートは、世界の同種幹細胞市場の競合情勢を詳しく掘り下げています。世界の同種幹細胞市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の同種幹細胞市場の企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 主要な洞察

  • 移植の動向に関する洞察
  • 技術の進歩
  • 地域/世界ごとの規制シナリオ
  • COVID-19パンデミックによる業界への影響（バリューチェーンと短期・中期・長期的な影響）

第6章 世界市場の分析と予測：タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：タイプ別、2017-2031
    • 未修飾幹細胞移植
    • T細胞除去移植
    • 臍帯血移植
    • ドナーリンパ球注入（DLI）
  • 市場魅力分析：タイプ別

第7章 世界市場の分析と予測：細胞源別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：細胞源別、2017-2031
    • 骨髄
    • 末梢血幹細胞（PBSC）
    • 臍帯血
    • 脂肪組織
    • その他
  • 市場魅力分析：細胞源別

第8章 世界市場の分析と予測：用途別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：用途別、2017-2031
    • 筋骨格系疾患
    • 循環器疾患
    • 自己免疫疾患
    • がん
    • GvHD
    • その他
  • 市場魅力分析：用途別

第9章 世界市場の分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：エンドユーザー別、2017-2031
    • 病院
    • 外来手術センター
    • その他
  • 市場魅力分析：エンドユーザー別

第10章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 国・地域別の市場魅力度

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東およびアフリカ市場の分析と予測

第16章 競合情勢

  • 市場企業- 競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Mesoblast Limited
    • Gamida Cell Ltd.
    • Novartis International AG
    • Cellectis SA
    • Magenta Therapeutics Inc.
    • Fate Therapeutics Inc.
    • Cynata Therapeutics Limited
    • Kiadis Pharma NV
    • Takeda Pharmaceutical Company Limited
    • JCR Pharmaceuticals Co., Ltd.
    • Pluristem Therapeutics Inc.
    • Celularity Inc.
    • Lineage Cell Therapeutics Inc.
    • Nohla Therapeutics Inc.
    • Orchard Therapeutics plc
    • その他の主要企業
図表

List of Tables

  • Table 01: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 02: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 03: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 04: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 08: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 09: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 10: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 11: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 13: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 14: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 15: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 16: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 18: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 19: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 20: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 23: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 24: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 25: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 28: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 29: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 30: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Allogeneic Stem Cell Market Value Share, by Type, 2022
  • Figure 03: Allogeneic Stem Cell Market Value Share, by Cell Source, 2022
  • Figure 04: Allogeneic Stem Cell Market Value Share, by Application, 2022
  • Figure 05: Allogeneic Stem Cell Market Value Share, by End-user, 2022
  • Figure 06: Global Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 07: Global Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 08: Global Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 09: Global Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
  • Figure 10: Global Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 11: Global Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
  • Figure 12: Global Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 13: Global Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 14: Global Allogeneic Stem Cell Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 15: Global Allogeneic Stem Cell Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 16: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 17: North America Allogeneic Stem Cell Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 18: North America Allogeneic Stem Cell Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 19: North America Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 20: North America Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 21: North America Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 22: North America Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
  • Figure 23: North America Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 24: North America Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
  • Figure 25: North America Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 26: North America Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 27: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: Europe Allogeneic Stem Cell Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 29: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 30: Europe Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 31: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 32: Europe Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 33: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
  • Figure 34: Europe Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 35: Europe Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
  • Figure 36: Europe Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 37: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 38: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 39: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 40: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 41: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 42: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 43: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 44: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
  • Figure 45: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 46: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
  • Figure 47: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 48: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 49: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 51: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 52: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 53: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 54: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 55: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source, 2023-2031
  • Figure 56: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 57: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
  • Figure 58: Latin America Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 59: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 60: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 62: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 63: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 64: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 65: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 66: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
  • Figure 67: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 68: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 69: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 70: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 71: Global Allogeneic Stem Cell Market Share Analysis By Company (2022)
目次
Product Code: TMRGL85776

Allogeneic Stem Cell Market - Scope of Report

TMR's report on the global allogeneic stem cell market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global allogeneic stem cell market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global allogeneic stem cell market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the allogeneic stem cell market.

Market Snapshot
Market Value in 2023US$ 941.8 Mn
Market Value in 2031US$ 1.6 Bn
CAGR6.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global allogeneic stem cell market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global allogeneic stem cell market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global allogeneic stem cell market.

The report delves into the competitive landscape of the global allogeneic stem cell market. Key players operating in the global allogeneic stem cell market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global allogeneic stem cell market profiled in this report.

Key Questions Answered in Global Allogeneic Stem Cell Market Report:

  • What is the sales/revenue generated by allogeneic stem cell across all regions during the forecast period?
  • What are the opportunities in the global allogeneic stem cell market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Allogeneic Stem Cell Market - Research Objectives and Research Approach

The comprehensive report on the global allogeneic stem cell market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global allogeneic stem cell market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global allogeneic stem cell market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Allogeneic Stem Cell Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Allogeneic Stem Cell Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Insights on Trends in Allogeneic Stem Cell Transplantation
  • 5.2. Technological Advancements
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Allogeneic Stem Cell Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. Unmodified Stem Cell Transplant
    • 6.3.2. T-cell Depleted Transplant
    • 6.3.3. Cord Blood Transplant
    • 6.3.4. Donor Lymphocyte Infusion (DLI)
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Allogeneic Stem Cell Market Analysis and Forecast, by Cell Source

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Cell Source, 2017-2031
    • 7.3.1. Bone Marrow
    • 7.3.2. Peripheral Blood Stem Cell (PBSC)
    • 7.3.3. Umbilical Cord Blood
    • 7.3.4. Adipose Tissue
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Cell Source

8. Global Allogeneic Stem Cell Market Analysis and Forecast, by Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Application, 2017-2031
    • 8.3.1. Musculoskeletal Disease
    • 8.3.2. Cardiovascular Disease
    • 8.3.3. Autoimmune Disease
    • 8.3.4. Cancer
    • 8.3.5. GvHD
    • 8.3.6. Others
  • 8.4. Market Attractiveness Analysis, by Application

9. Global Allogeneic Stem Cell Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Hospital
    • 9.3.2. Ambulatory Surgical Center
    • 9.3.3. Others
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Allogeneic Stem Cell Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Country/Region

11. North America Allogeneic Stem Cell Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type, 2017-2031
    • 11.2.1. Unmodified Stem Cell Transplant
    • 11.2.2. T-cell Depleted Transplant
    • 11.2.3. Cord Blood Transplant
    • 11.2.4. Donor Lymphocyte Infusion (DLI)
  • 11.3. Market Value Forecast, by Cell Source, 2017-2031
    • 11.3.1. Bone Marrow
    • 11.3.2. Peripheral Blood Stem Cell (PBSC)
    • 11.3.3. Umbilical Cord Blood
    • 11.3.4. Adipose Tissue
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Application, 2017-2031
    • 11.4.1. Musculoskeletal Disease
    • 11.4.2. Cardiovascular Disease
    • 11.4.3. Autoimmune Disease
    • 11.4.4. Cancer
    • 11.4.5. GvHD
    • 11.4.6. Others
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Hospital
    • 11.5.2. Ambulatory Surgical Center
    • 11.5.3. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Cell Source
    • 11.7.3. By Application
    • 11.7.4. By End-user
    • 11.7.5. By Country/Sub-region

12. Europe Allogeneic Stem Cell Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type, 2017-2031
    • 12.2.1. Unmodified Stem Cell Transplant
    • 12.2.2. T-cell Depleted Transplant
    • 12.2.3. Cord Blood Transplant
    • 12.2.4. Donor Lymphocyte Infusion (DLI)
  • 12.3. Market Value Forecast, by Cell Source, 2017-2031
    • 12.3.1. Bone Marrow
    • 12.3.2. Peripheral Blood Stem Cell (PBSC)
    • 12.3.3. Umbilical Cord Blood
    • 12.3.4. Adipose Tissue
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Application, 2017-2031
    • 12.4.1. Musculoskeletal Disease
    • 12.4.2. Cardiovascular Disease
    • 12.4.3. Autoimmune Disease
    • 12.4.4. Cancer
    • 12.4.5. GvHD
    • 12.4.6. Others
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Hospital
    • 12.5.2. Ambulatory Surgical Center
    • 12.5.3. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Cell Source
    • 12.7.3. By Application
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Allogeneic Stem Cell Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type, 2017-2031
    • 13.2.1. Unmodified Stem Cell Transplant
    • 13.2.2. T-cell Depleted Transplant
    • 13.2.3. Cord Blood Transplant
    • 13.2.4. Donor Lymphocyte Infusion (DLI)
  • 13.3. Market Value Forecast, by Cell Source, 2017-2031
    • 13.3.1. Bone Marrow
    • 13.3.2. Peripheral Blood Stem Cell (PBSC)
    • 13.3.3. Umbilical Cord Blood
    • 13.3.4. Adipose Tissue
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Application, 2017-2031
    • 13.4.1. Musculoskeletal Disease
    • 13.4.2. Cardiovascular Disease
    • 13.4.3. Autoimmune Disease
    • 13.4.4. Cancer
    • 13.4.5. GvHD
    • 13.4.6. Others
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Hospital
    • 13.5.2. Ambulatory Surgical Center
    • 13.5.3. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Cell Source
    • 13.7.3. By Application
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Allogeneic Stem Cell Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type, 2017-2031
    • 14.2.1. Unmodified Stem Cell Transplant
    • 14.2.2. T-cell Depleted Transplant
    • 14.2.3. Cord Blood Transplant
    • 14.2.4. Donor Lymphocyte Infusion (DLI)
  • 14.3. Market Value Forecast, by Cell Source, 2017-2031
    • 14.3.1. Bone Marrow
    • 14.3.2. Peripheral Blood Stem Cell (PBSC)
    • 14.3.3. Umbilical Cord Blood
    • 14.3.4. Adipose Tissue
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Application, 2017-2031
    • 14.4.1. Musculoskeletal Disease
    • 14.4.2. Cardiovascular Disease
    • 14.4.3. Autoimmune Disease
    • 14.4.4. Cancer
    • 14.4.5. GvHD
    • 14.4.6. Others
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Hospital
    • 14.5.2. Ambulatory Surgical Center
    • 14.5.3. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Cell Source
    • 14.7.3. By Application
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Allogeneic Stem Cell Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Type, 2017-2031
    • 15.2.1. Unmodified Stem Cell Transplant
    • 15.2.2. T-cell Depleted Transplant
    • 15.2.3. Cord Blood Transplant
    • 15.2.4. Donor Lymphocyte Infusion (DLI)
  • 15.3. Market Value Forecast, by Cell Source, 2017-2031
    • 15.3.1. Bone Marrow
    • 15.3.2. Peripheral Blood Stem Cell (PBSC)
    • 15.3.3. Umbilical Cord Blood
    • 15.3.4. Adipose Tissue
    • 15.3.5. Others
  • 15.4. Market Value Forecast, by Application, 2017-2031
    • 15.4.1. Musculoskeletal Disease
    • 15.4.2. Cardiovascular Disease
    • 15.4.3. Autoimmune Disease
    • 15.4.4. Cancer
    • 15.4.5. GvHD
    • 15.4.6. Others
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Hospital
    • 15.5.2. Ambulatory Surgical Center
    • 15.5.3. Others
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Type
    • 15.7.2. By Cell Source
    • 15.7.3. By Application
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Mesoblast Limited
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Gamida Cell Ltd.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Novartis International AG
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Cellectis SA
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Magenta Therapeutics Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Fate Therapeutics Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Cynata Therapeutics Limited
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Kiadis Pharma N.V.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Takeda Pharmaceutical Company Limited
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. JCR Pharmaceuticals Co., Ltd.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Pluristem Therapeutics Inc.
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Celularity Inc.
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview
    • 16.3.13. Lineage Cell Therapeutics Inc.
      • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.13.2. Product Portfolio
      • 16.3.13.3. Financial Overview
      • 16.3.13.4. SWOT Analysis
      • 16.3.13.5. Strategic Overview
    • 16.3.14. Nohla Therapeutics Inc.
      • 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.14.2. Product Portfolio
      • 16.3.14.3. Financial Overview
      • 16.3.14.4. SWOT Analysis
      • 16.3.14.5. Strategic Overview
    • 16.3.15. Orchard Therapeutics plc
      • 16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.15.2. Product Portfolio
      • 16.3.15.3. Financial Overview
      • 16.3.15.4. SWOT Analysis
      • 16.3.15.5. Strategic Overview
    • 16.3.16. Other Prominent Players
      • 16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.16.2. Product Portfolio
      • 16.3.16.3. Financial Overview
      • 16.3.16.4. SWOT Analysis
      • 16.3.16.5. Strategic Overview